FDA FAERS Adverse Event Reports

111000
Total Reports
60668
Serious Reports
108
Reporter Countries
Clear
25957247 Type 1
Serious
TAFAMIDIS
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/18/2026
Primary Source Country
EU
Occurrence Country
EU
Reporter Country
EU
Reporter Qualification
Physician
Literature Reference
--
Company Number
EU-PFIZER INC-202500209382
Authority Number
--
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
86.0 yr
Patient Age Group
--
Patient Sex
Male
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Renal failure (v28.1) Not Recovered

Drugs (1)

TAFAMIDIS (TAFAMIDIS) Suspect
Route: -- | Dosage: UNK | Form: Capsule, soft | Indication: Cardiac amyloidosis | Action: Unknown
Auth#: 212161 | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --

Clinical Narrative

--

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56690", "safetyreportid": "25957247", "authoritynumb": null, "companynumb": "EU-PFIZER INC-202500209382", "duplicate": null, "fulfillexpeditecriteria": 1, "occurcountry": "EU", "patient": { "patientonsetage": 86.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Renal failure", "reactionoutcome": 3 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TAFAMIDIS", "drugauthorizationnumb": "212161", "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "UNK", "drugdosageform": "Capsule, soft", "drugadministrationroute": null, "drugindication": "Cardiac amyloidosis", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "TAFAMIDIS" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "EU", "qualification": 1, "literaturereference": null }, "primarysourcecountry": "EU", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25957239 Type 1
Serious
TOBRAMYCIN, TOBRAMYCIN, TOBRAMYCIN (+23 more)
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/18/2026
Primary Source Country
GB
Occurrence Country
GB
Reporter Country
GB
Reporter Qualification
Pharmacist
Literature Reference
--
Company Number
GB-BAXTER-2024BAX010373
Authority Number
--
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
38.0 yr
Patient Age Group
--
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (7)

General physical health deterioration (v28.1) Unknown
Malaise (v28.1) Unknown
Oxygen saturation decreased (v28.1) Unknown
Dyspnoea (v28.1) Unknown
Weight decreased (v28.1) Unknown
Nutritional condition abnormal (v28.1) Unknown
Haemoptysis (v28.1) Unknown

Drugs (26)

TOBRAMYCIN (TOBRAMYCIN) Suspect
Route: 042 | Dosage: 340 MG ONCE A DAY, AS A DUAL THERAPY ALONGSIDE FOSFOMYCI | Form: -- | Indication: Cystic fibrosis | Action: Unknown
Auth#: 063111 | Batch#: -- | Structured Dosage: 340.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
TOBRAMYCIN (TOBRAMYCIN) Suspect
Route: 042 | Dosage: 2 WEEKS COURSE | Form: -- | Indication: Condition aggravated | Action: Unknown
Auth#: 063111 | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: 02/29/2024 | End: 03/06/2024 | Duration: 7.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
TOBRAMYCIN (TOBRAMYCIN) Suspect
Route: 042 | Dosage: 330 MG, DAILY (2 WEEKS IN TOTAL TO COMPLETE AT HOME) | Form: -- | Indication: Infection | Action: Unknown
Auth#: 063111 | Batch#: -- | Structured Dosage: 330.0 (unit: 003) | Separate Dosage#: -- | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 12/23/2023 | End: 01/02/2024 | Duration: 11.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
COLISTIN SULFATE (COLISTIN SULFATE) Suspect
Route: 042 | Dosage: 2 MU THRICE A DAY FOR 8 DAYS | Form: -- | Indication: Infection | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
COLISTIN SULFATE (COLISTIN SULFATE) Suspect
Route: 042 | Dosage: 2 MU THRICE A DAY | Form: -- | Indication: Cystic fibrosis | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 11/30/2023 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
COLISTIN SULFATE (COLISTIN SULFATE) Suspect
Route: 042 | Dosage: 2 MU THRICE A DAY, AS A DUAL THERAPY ALONGSIDE FOSFOMYCIN | Form: -- | Indication: Condition aggravated | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 12/19/2023 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 4 G THRICE A DAY | Form: -- | Indication: Infection | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: 4.0 (unit: 002) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 11/30/2023 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY FOR 13 DAYS, AS A DUAL THERAPY ALONGSIDE 2 MU COLOMYCIN | Form: -- | Indication: Cystic fibrosis | Action: Unknown
Auth#: -- | Batch#: F0522401 | Structured Dosage: 2000.0 (unit: 003) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 12/19/2023 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY FOR 8 DAYS, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN | Form: -- | Indication: Condition aggravated | Action: Unknown
Auth#: -- | Batch#: F0622421 | Structured Dosage: 2000.0 (unit: 003) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN AND 2 MU COLOMYCIN | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: F0622421 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 2 MU COLOMYCIN | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: F0522401 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 2 MU COLOMYCIN | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: F0522401 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN AND 2 MU COLOMYCIN | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: F0522401 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN AND 2 MU COLOMYCIN | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: F0522401 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 12 G, DAILY | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: 12.0 (unit: 002) | Separate Dosage#: -- | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 12/23/2023 | End: 01/02/2024 | Duration: 11.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2 WEEKS COURSE | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: 09/26/2024 | End: 10/08/2024 | Duration: 13.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
FOSFOMYCIN (FOSFOMYCIN) Suspect
Route: 042 | Dosage: 2 WEEKS COURSE | Form: -- | Indication: -- | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: 02/29/2024 | End: 03/08/2024 | Duration: 9.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: 042 | Dosage: 250 ML THRICE A DAY FOR 13 DAYS | Form: Solution for infusion | Indication: Medication dilution | Action: Unknown
Auth#: -- | Batch#: 23D21T2C | Structured Dosage: 250.0 (unit: 012) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 12/19/2023 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: 042 | Dosage: 250 ML THRICE A DAY FOR 8 DAYS | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23I13T2C | Structured Dosage: 250.0 (unit: 012) | Separate Dosage#: 3.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23D21T2C | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23D21T2C | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23I13T2C | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23D21T2C | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23D21T2C | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
DEXTROSE MONOHYDRATE (DEXTROSE MONOHYDRATE) Suspect
Route: -- | Dosage: 250 ML THRICE A DAY | Form: Solution for infusion | Indication: -- | Action: Unknown
Auth#: -- | Batch#: 23D21T2C | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20231223

Report Duplicates (2)

MHRA: GB-MHRA-ADR 28516817
BAXTER: GB-BAXTER-2024BAX010373

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa5668e", "safetyreportid": "25957239", "authoritynumb": null, "companynumb": "GB-BAXTER-2024BAX010373", "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "GB", "patient": { "patientonsetage": 38.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "General physical health deterioration", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Malaise", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Oxygen saturation decreased", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Dyspnoea", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Weight decreased", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Nutritional condition abnormal", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Haemoptysis", "reactionoutcome": 6 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TOBRAMYCIN", "drugauthorizationnumb": "063111", "drugbatchnumb": null, "drugstructuredosagenumb": 340.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "340 MG ONCE A DAY, AS A DUAL THERAPY ALONGSIDE FOSFOMYCI", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Cystic fibrosis", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "TOBRAMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "TOBRAMYCIN", "drugauthorizationnumb": "063111", "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2 WEEKS COURSE", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Condition aggravated", "drugstartdateformat": "102", "drugstartdate": "2024-02-29T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-03-06T00:00:00", "drugtreatmentduration": 7.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "TOBRAMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "TOBRAMYCIN", "drugauthorizationnumb": "063111", "drugbatchnumb": null, "drugstructuredosagenumb": 330.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "330 MG, DAILY (2 WEEKS IN TOTAL TO COMPLETE AT HOME)", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Infection", "drugstartdateformat": "102", "drugstartdate": "2023-12-23T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-01-02T00:00:00", "drugtreatmentduration": 11.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "TOBRAMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "COLISTIN SULFATE", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2 MU THRICE A DAY FOR 8 DAYS", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Infection", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "COLISTIN SULFATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "COLISTIN SULFATE", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2 MU THRICE A DAY", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Cystic fibrosis", "drugstartdateformat": "102", "drugstartdate": "2023-11-30T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "COLISTIN SULFATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "COLISTIN SULFATE", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2 MU THRICE A DAY, AS A DUAL THERAPY ALONGSIDE FOSFOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Condition aggravated", "drugstartdateformat": "102", "drugstartdate": "2023-12-19T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "COLISTIN SULFATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": 4.0, "drugstructuredosageunit": "002", "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "4 G THRICE A DAY", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Infection", "drugstartdateformat": "102", "drugstartdate": "2023-11-30T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0522401", "drugstructuredosagenumb": 2000.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY FOR 13 DAYS, AS A DUAL THERAPY ALONGSIDE 2 MU COLOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Cystic fibrosis", "drugstartdateformat": "102", "drugstartdate": "2023-12-19T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0622421", "drugstructuredosagenumb": 2000.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY FOR 8 DAYS, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Condition aggravated", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0622421", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN AND 2 MU COLOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0522401", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 2 MU COLOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0522401", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 2 MU COLOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0522401", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN AND 2 MU COLOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": "F0522401", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2000 MG THRICE A DAY, AS A DUAL THERAPY ALONGSIDE 340 MG TOBRAMYCIN AND 2 MU COLOMYCIN", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": 12.0, "drugstructuredosageunit": "002", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "12 G, DAILY", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": "102", "drugstartdate": "2023-12-23T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-01-02T00:00:00", "drugtreatmentduration": 11.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2 WEEKS COURSE", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": "102", "drugstartdate": "2024-09-26T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-10-08T00:00:00", "drugtreatmentduration": 13.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "FOSFOMYCIN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "2 WEEKS COURSE", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": "102", "drugstartdate": "2024-02-29T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-03-08T00:00:00", "drugtreatmentduration": 9.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FOSFOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23D21T2C", "drugstructuredosagenumb": 250.0, "drugstructuredosageunit": "012", "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY FOR 13 DAYS", "drugdosageform": "Solution for infusion", "drugadministrationroute": "042", "drugindication": "Medication dilution", "drugstartdateformat": "102", "drugstartdate": "2023-12-19T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23I13T2C", "drugstructuredosagenumb": 250.0, "drugstructuredosageunit": "012", "drugseparatedosagenumb": 3.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY FOR 8 DAYS", "drugdosageform": "Solution for infusion", "drugadministrationroute": "042", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23D21T2C", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23D21T2C", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23I13T2C", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23D21T2C", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23D21T2C", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "DEXTROSE MONOHYDRATE", "drugauthorizationnumb": null, "drugbatchnumb": "23D21T2C", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "250 ML THRICE A DAY", "drugdosageform": "Solution for infusion", "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "DEXTROSE MONOHYDRATE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20231223" }, "primarysource": { "reportercountry": "GB", "qualification": 2, "literaturereference": null }, "primarysourcecountry": "GB", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "MHRA", "duplicatenumb": "GB-MHRA-ADR 28516817" }, { "duplicatesource": "BAXTER", "duplicatenumb": "GB-BAXTER-2024BAX010373" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 1, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25957245 Type 1
Serious
DAPTOMYCIN, CLOXACILLIN
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/17/2026
Primary Source Country
EU
Occurrence Country
EU
Reporter Country
EU
Reporter Qualification
Physician
Literature Reference
--
Company Number
--
Authority Number
EU-AFSSAPS-RS2025001013
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
64.0 yr
Patient Age Group
--
Patient Sex
Male
Patient Weight
76.8 kg

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Renal tubular disorder (v28.1) Recovered

Drugs (2)

DAPTOMYCIN (DAPTOMYCIN) Suspect
Route: 042 | Dosage: 750 MG, 1X/DAY | Form: Powder for injection | Indication: Staphylococcal bacteraemia | Action: Withdrawn
Auth#: 210282 | Batch#: -- | Structured Dosage: 750.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 3214.286 (unit: 003)
Start: 08/08/2024 | End: 08/14/2024 | Duration: 6.0 day | Rechallenge: -- | Additional: Yes
Recurrences: --
CLOXACILLIN (CLOXACILLIN) Suspect
Route: 042 | Dosage: 12 G, 1X/DAY | Form: -- | Indication: Staphylococcal bacteraemia | Action: Withdrawn
Auth#: -- | Batch#: -- | Structured Dosage: 12.0 (unit: 002) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 110.0 (unit: 002)
Start: 08/03/2024 | End: 08/14/2024 | Duration: 11.0 day | Rechallenge: -- | Additional: Yes
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20240812

Report Duplicates (1)

AFSSAPS: EU-AFSSAPS-RS2025001013

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56693", "safetyreportid": "25957245", "authoritynumb": "EU-AFSSAPS-RS2025001013", "companynumb": null, "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "EU", "patient": { "patientonsetage": 64.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": 76.8, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Renal tubular disorder", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "DAPTOMYCIN", "drugauthorizationnumb": "210282", "drugbatchnumb": null, "drugstructuredosagenumb": 750.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 3214.286, "drugcumulativedosageunit": "003", "drugdosagetext": "750 MG, 1X/DAY", "drugdosageform": "Powder for injection", "drugadministrationroute": "042", "drugindication": "Staphylococcal bacteraemia", "drugstartdateformat": "102", "drugstartdate": "2024-08-08T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-08-14T00:00:00", "drugtreatmentduration": 6.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 1, "actiondrug": 1, "activesubstance": { "activesubstancename": "DAPTOMYCIN" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "CLOXACILLIN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": 12.0, "drugstructuredosageunit": "002", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 110.0, "drugcumulativedosageunit": "002", "drugdosagetext": "12 G, 1X/DAY", "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Staphylococcal bacteraemia", "drugstartdateformat": "102", "drugstartdate": "2024-08-03T00:00:00", "drugenddateformat": "102", "drugenddate": "2024-08-14T00:00:00", "drugtreatmentduration": 11.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 1, "actiondrug": 1, "activesubstance": { "activesubstancename": "CLOXACILLIN" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20240812" }, "primarysource": { "reportercountry": "EU", "qualification": 1, "literaturereference": null }, "primarysourcecountry": "EU", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "AFSSAPS", "duplicatenumb": "EU-AFSSAPS-RS2025001013" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-17T00:00:00", "transmissiondateformat": "102" }
25957249 Type 1
Serious
TYGACIL, TYGACIL
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/17/2026
Primary Source Country
CN
Occurrence Country
CN
Reporter Country
CN
Reporter Qualification
Other Health Professional
Literature Reference
--
Company Number
CN-PFIZER INC-PV202500124782
Authority Number
--
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
74.0 yr
Patient Age Group
--
Patient Sex
Male
Patient Weight
50.0 kg

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (2)

Lipase increased (v28.1) Recovering
Amylase increased (v28.1) Recovering

Drugs (2)

TYGACIL (TIGECYCLINE) Suspect
Route: 041 | Dosage: 100 MG, 1X/DAY (INITIAL DOSE) | Form: Injection | Indication: Anti-infective therapy | Action: Not Applicable
Auth#: 21821 | Batch#: ANKJ/12 | Structured Dosage: 100.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 1000.0 (unit: 003)
Start: 05/20/2025 | End: 05/20/2025 | Duration: 1.0 day | Rechallenge: -- | Additional: 4
Recurrences: --
TYGACIL (TIGECYCLINE) Suspect
Route: 041 | Dosage: 50 MG, 2X/DAY | Form: Injection | Indication: Pneumonia | Action: Not Applicable
Auth#: 21821 | Batch#: ANKJ/12 | Structured Dosage: 50.0 (unit: 003) | Separate Dosage#: 2.0 | Interval: 1.0 day | Cumulative: 1000.0 (unit: 003)
Start: 05/20/2025 | End: 05/28/2025 | Duration: 9.0 day | Rechallenge: -- | Additional: 4
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250530

Report Duplicates (1)

National Center for Adverse Drug Reaction Monitori: 4401041006500202500361

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56692", "safetyreportid": "25957249", "authoritynumb": null, "companynumb": "CN-PFIZER INC-PV202500124782", "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "CN", "patient": { "patientonsetage": 74.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": 50.0, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Lipase increased", "reactionoutcome": 2 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Amylase increased", "reactionoutcome": 2 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TYGACIL", "drugauthorizationnumb": "21821", "drugbatchnumb": "ANKJ/12", "drugstructuredosagenumb": 100.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 1000.0, "drugcumulativedosageunit": "003", "drugdosagetext": "100 MG, 1X/DAY (INITIAL DOSE)", "drugdosageform": "Injection", "drugadministrationroute": "041", "drugindication": "Anti-infective therapy", "drugstartdateformat": "102", "drugstartdate": "2025-05-20T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-05-20T00:00:00", "drugtreatmentduration": 1.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TIGECYCLINE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "TYGACIL", "drugauthorizationnumb": "21821", "drugbatchnumb": "ANKJ/12", "drugstructuredosagenumb": 50.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 2.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 1000.0, "drugcumulativedosageunit": "003", "drugdosagetext": "50 MG, 2X/DAY", "drugdosageform": "Injection", "drugadministrationroute": "041", "drugindication": "Pneumonia", "drugstartdateformat": "102", "drugstartdate": "2025-05-20T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-05-28T00:00:00", "drugtreatmentduration": 9.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TIGECYCLINE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250530" }, "primarysource": { "reportercountry": "CN", "qualification": 3, "literaturereference": null }, "primarysourcecountry": "CN", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "National Center for Adverse Drug Reaction Monitori", "duplicatenumb": "4401041006500202500361" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 1, "seriousnesslifethreatening": 1, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-17T00:00:00", "transmissiondateformat": "102" }
25957240 Type 1
Non-Serious
OFEV
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/17/2026
Primary Source Country
US
Occurrence Country
--
Reporter Country
US
Reporter Qualification
Consumer
Literature Reference
--
Company Number
--
Authority Number
783616
Sender Organization
FDA-CTU
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
3
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
--
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Diarrhoea (v28.1) --

Drugs (1)

OFEV (NINTEDANIB) Suspect
Route: -- | Dosage: -- | Form: -- | Indication: -- | Action: --
Auth#: -- | Batch#: Unknown | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: --
Recurrences: --

Clinical Narrative

--

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa5668c", "safetyreportid": "25957240", "authoritynumb": "783616", "companynumb": null, "duplicate": null, "fulfillexpeditecriteria": 3, "occurcountry": null, "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": null, "patientsex": null, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Diarrhoea", "reactionoutcome": null } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "OFEV", "drugauthorizationnumb": null, "drugbatchnumb": "Unknown", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": null, "actiondrug": null, "activesubstance": { "activesubstancename": "NINTEDANIB" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "US", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "FDA-CTU" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-17T00:00:00", "transmissiondateformat": "102" }
25957236 Type 1
Serious
CYTARABINE, CYTARABINE, ETOPOSIDE (+2 more)
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/18/2026
Primary Source Country
CN
Occurrence Country
CN
Reporter Country
CN
Reporter Qualification
Other Health Professional
Literature Reference
--
Company Number
CN-PFIZER INC-PV202500124804
Authority Number
--
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
42.0 yr
Patient Age Group
--
Patient Sex
Male
Patient Weight
50.0 kg

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (11)

Myelosuppression (v28.1) Recovering
Rash (v28.1) Recovering
Hepatic function abnormal (v28.1) Recovering
Pruritus (v28.1) Unknown
Erythema (v28.1) Unknown
Swelling (v28.1) Unknown
Febrile infection (v28.1) Recovered
Chills (v28.1) Unknown
Asthenia (v28.1) Unknown
Hyperhidrosis (v28.1) Unknown
Diarrhoea (v28.1) Unknown

Drugs (5)

CYTARABINE (CYTARABINE) Suspect
Route: 041 | Dosage: 70 MG, 1X/DAY | Form: Powder for solution for injection | Indication: Chemotherapy | Action: Not Applicable
Auth#: 071868 | Batch#: LN1340 | Structured Dosage: 70.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 350.0 (unit: 003)
Start: 09/17/2025 | End: 09/21/2025 | Duration: 5.0 day | Rechallenge: -- | Additional: 4
Recurrences: --
CYTARABINE (CYTARABINE) Suspect
Route: 041 | Dosage: 3 G, 1X/DAY | Form: Powder for solution for injection | Indication: Chemotherapy | Action: Not Applicable
Auth#: 071868 | Batch#: LY7768 | Structured Dosage: 3.0 (unit: 002) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 12.0 (unit: 002)
Start: 09/18/2025 | End: 09/21/2025 | Duration: 4.0 day | Rechallenge: -- | Additional: 4
Recurrences: --
ETOPOSIDE (ETOPOSIDE) Suspect
Route: 041 | Dosage: 0.3 G, 1X/DAY | Form: Injection | Indication: Chemotherapy | Action: Not Applicable
Auth#: -- | Batch#: AB1K4005 | Structured Dosage: 0.3 (unit: 002) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 1.2 (unit: 002)
Start: 09/18/2025 | End: 09/21/2025 | Duration: 4.0 day | Rechallenge: -- | Additional: 4
Recurrences: --
SODIUM CHLORIDE (SODIUM CHLORIDE) Concomitant
Route: 041 | Dosage: 500 ML, 1X/DAY | Form: Injection | Indication: Vehicle solution use | Action: --
Auth#: -- | Batch#: 24M08C01 | Structured Dosage: 500.0 (unit: 012) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 2000.0 (unit: 012)
Start: 09/18/2025 | End: 09/21/2025 | Duration: 4.0 day | Rechallenge: -- | Additional: --
Recurrences: --
SODIUM CHLORIDE (SODIUM CHLORIDE) Concomitant
Route: 041 | Dosage: 250 ML, 1X/DAY | Form: Injection | Indication: Vehicle solution use | Action: --
Auth#: -- | Batch#: Q2405029 | Structured Dosage: 250.0 (unit: 012) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: 1250.0 (unit: 012)
Start: 09/17/2025 | End: 09/21/2025 | Duration: 5.0 day | Rechallenge: -- | Additional: --
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250922

Report Duplicates (1)

National Center for Adverse Drug Reaction Monitori: 2102131012538202500193

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56689", "safetyreportid": "25957236", "authoritynumb": null, "companynumb": "CN-PFIZER INC-PV202500124804", "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "CN", "patient": { "patientonsetage": 42.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": 50.0, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Myelosuppression", "reactionoutcome": 2 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Rash", "reactionoutcome": 2 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Hepatic function abnormal", "reactionoutcome": 2 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Pruritus", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Erythema", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Swelling", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Febrile infection", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Chills", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Asthenia", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Hyperhidrosis", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Diarrhoea", "reactionoutcome": 6 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "CYTARABINE", "drugauthorizationnumb": "071868", "drugbatchnumb": "LN1340", "drugstructuredosagenumb": 70.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 350.0, "drugcumulativedosageunit": "003", "drugdosagetext": "70 MG, 1X/DAY", "drugdosageform": "Powder for solution for injection", "drugadministrationroute": "041", "drugindication": "Chemotherapy", "drugstartdateformat": "102", "drugstartdate": "2025-09-17T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-21T00:00:00", "drugtreatmentduration": 5.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "CYTARABINE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "CYTARABINE", "drugauthorizationnumb": "071868", "drugbatchnumb": "LY7768", "drugstructuredosagenumb": 3.0, "drugstructuredosageunit": "002", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 12.0, "drugcumulativedosageunit": "002", "drugdosagetext": "3 G, 1X/DAY", "drugdosageform": "Powder for solution for injection", "drugadministrationroute": "041", "drugindication": "Chemotherapy", "drugstartdateformat": "102", "drugstartdate": "2025-09-18T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-21T00:00:00", "drugtreatmentduration": 4.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "CYTARABINE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "ETOPOSIDE", "drugauthorizationnumb": null, "drugbatchnumb": "AB1K4005", "drugstructuredosagenumb": 0.3, "drugstructuredosageunit": "002", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 1.2, "drugcumulativedosageunit": "002", "drugdosagetext": "0.3 G, 1X/DAY", "drugdosageform": "Injection", "drugadministrationroute": "041", "drugindication": "Chemotherapy", "drugstartdateformat": "102", "drugstartdate": "2025-09-18T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-21T00:00:00", "drugtreatmentduration": 4.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "ETOPOSIDE" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "SODIUM CHLORIDE", "drugauthorizationnumb": null, "drugbatchnumb": "24M08C01", "drugstructuredosagenumb": 500.0, "drugstructuredosageunit": "012", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 2000.0, "drugcumulativedosageunit": "012", "drugdosagetext": "500 ML, 1X/DAY", "drugdosageform": "Injection", "drugadministrationroute": "041", "drugindication": "Vehicle solution use", "drugstartdateformat": "102", "drugstartdate": "2025-09-18T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-21T00:00:00", "drugtreatmentduration": 4.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": null, "actiondrug": null, "activesubstance": { "activesubstancename": "SODIUM CHLORIDE" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "SODIUM CHLORIDE", "drugauthorizationnumb": null, "drugbatchnumb": "Q2405029", "drugstructuredosagenumb": 250.0, "drugstructuredosageunit": "012", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": 1250.0, "drugcumulativedosageunit": "012", "drugdosagetext": "250 ML, 1X/DAY", "drugdosageform": "Injection", "drugadministrationroute": "041", "drugindication": "Vehicle solution use", "drugstartdateformat": "102", "drugstartdate": "2025-09-17T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-21T00:00:00", "drugtreatmentduration": 5.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": null, "actiondrug": null, "activesubstance": { "activesubstancename": "SODIUM CHLORIDE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250922" }, "primarysource": { "reportercountry": "CN", "qualification": 3, "literaturereference": null }, "primarysourcecountry": "CN", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "National Center for Adverse Drug Reaction Monitori", "duplicatenumb": "2102131012538202500193" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 1, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25957235 Type 1
Serious
SULFASALAZINE, SULFASALAZINE, RIVAROXABAN (+1 more)
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/19/2026
Primary Source Country
EU
Occurrence Country
EU
Reporter Country
EU
Reporter Qualification
Physician
Literature Reference
--
Company Number
--
Authority Number
EU-MINISAL02-1061715
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
77.0 yr
Patient Age Group
--
Patient Sex
Male
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (4)

Laryngeal obstruction (v28.1) Recovered
Malaise (v28.1) Recovered
Band sensation (v28.1) Recovered
Dizziness (v28.1) Recovered

Drugs (4)

SULFASALAZINE (SULFASALAZINE) Suspect
Route: 048 | Dosage: 500 MG, 1X/DAY (ONE TABLET IN THE EVENING (STARTING DOSE) | Form: -- | Indication: Tenosynovitis | Action: Withdrawn
Auth#: 7073 | Batch#: -- | Structured Dosage: 500.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 09/23/2025 | End: 09/25/2025 | Duration: 3.0 day | Rechallenge: -- | Additional: Yes
Recurrences: --
SULFASALAZINE (SULFASALAZINE) Suspect
Route: -- | Dosage: -- | Form: -- | Indication: Rheumatoid arthritis | Action: Withdrawn
Auth#: 7073 | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Yes
Recurrences: --
RIVAROXABAN (RIVAROXABAN) Concomitant
Route: 048 | Dosage: UNK, 1X/DAY (ONE TABLET DAILY) | Form: -- | Indication: Atrial fibrillation | Action: --
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 07/30/2018 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: --
Recurrences: --
NEBIVOLOL (NEBIVOLOL) Concomitant
Route: 048 | Dosage: 5 MG, 1X/DAY (ONE 5 MG TABLET/DAY) | Form: -- | Indication: -- | Action: --
Auth#: -- | Batch#: -- | Structured Dosage: 5.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: 09/23/2011 | End: -- | Duration: -- -- | Rechallenge: -- | Additional: --
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250923

Report Duplicates (1)

MINISAL02: EU-MINISAL02-1061715

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56688", "safetyreportid": "25957235", "authoritynumb": "EU-MINISAL02-1061715", "companynumb": null, "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "EU", "patient": { "patientonsetage": 77.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Laryngeal obstruction", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Malaise", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Band sensation", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Dizziness", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "SULFASALAZINE", "drugauthorizationnumb": "7073", "drugbatchnumb": null, "drugstructuredosagenumb": 500.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "500 MG, 1X/DAY (ONE TABLET IN THE EVENING (STARTING DOSE)", "drugdosageform": null, "drugadministrationroute": "048", "drugindication": "Tenosynovitis", "drugstartdateformat": "102", "drugstartdate": "2025-09-23T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-25T00:00:00", "drugtreatmentduration": 3.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 1, "actiondrug": 1, "activesubstance": { "activesubstancename": "SULFASALAZINE" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "SULFASALAZINE", "drugauthorizationnumb": "7073", "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": null, "drugindication": "Rheumatoid arthritis", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 1, "actiondrug": 1, "activesubstance": { "activesubstancename": "SULFASALAZINE" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "RIVAROXABAN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "UNK, 1X/DAY (ONE TABLET DAILY)", "drugdosageform": null, "drugadministrationroute": "048", "drugindication": "Atrial fibrillation", "drugstartdateformat": "102", "drugstartdate": "2018-07-30T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": null, "actiondrug": null, "activesubstance": { "activesubstancename": "RIVAROXABAN" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "NEBIVOLOL", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": 5.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "5 MG, 1X/DAY (ONE 5 MG TABLET/DAY)", "drugdosageform": null, "drugadministrationroute": "048", "drugindication": null, "drugstartdateformat": "102", "drugstartdate": "2011-09-23T00:00:00", "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": null, "actiondrug": null, "activesubstance": { "activesubstancename": "NEBIVOLOL" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250923" }, "primarysource": { "reportercountry": "EU", "qualification": 1, "literaturereference": null }, "primarysourcecountry": "EU", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "MINISAL02", "duplicatenumb": "EU-MINISAL02-1061715" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-19T00:00:00", "transmissiondateformat": "102" }
25957234 Type 1
Serious
METHOTREXATE SODIUM, SULFASALAZINE
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/19/2026
Primary Source Country
CA
Occurrence Country
CA
Reporter Country
CA
Reporter Qualification
Other Health Professional
Literature Reference
--
Company Number
CA-PFIZER INC-202500208547
Authority Number
--
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
77.0 yr
Patient Age Group
--
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (2)

Neoplasm malignant (v28.1) Unknown
Positron emission tomogram abnormal (v28.1) Not Recovered

Drugs (2)

METHOTREXATE SODIUM (METHOTREXATE SODIUM) Suspect
Route: -- | Dosage: 1 DF | Form: -- | Indication: -- | Action: Unknown
Auth#: 011719 | Batch#: -- | Structured Dosage: 1.0 (unit: 032) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
SULFASALAZINE (SULFASALAZINE) Suspect
Route: -- | Dosage: 1 DF | Form: -- | Indication: -- | Action: Unknown
Auth#: 7073 | Batch#: -- | Structured Dosage: 1.0 (unit: 032) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20251020

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56687", "safetyreportid": "25957234", "authoritynumb": null, "companynumb": "CA-PFIZER INC-202500208547", "duplicate": null, "fulfillexpeditecriteria": 1, "occurcountry": "CA", "patient": { "patientonsetage": 77.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Neoplasm malignant", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Positron emission tomogram abnormal", "reactionoutcome": 3 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "METHOTREXATE SODIUM", "drugauthorizationnumb": "011719", "drugbatchnumb": null, "drugstructuredosagenumb": 1.0, "drugstructuredosageunit": "032", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "1 DF", "drugdosageform": null, "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "METHOTREXATE SODIUM" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "SULFASALAZINE", "drugauthorizationnumb": "7073", "drugbatchnumb": null, "drugstructuredosagenumb": 1.0, "drugstructuredosageunit": "032", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "1 DF", "drugdosageform": null, "drugadministrationroute": null, "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "SULFASALAZINE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20251020" }, "primarysource": { "reportercountry": "CA", "qualification": 3, "literaturereference": null }, "primarysourcecountry": "CA", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-19T00:00:00", "transmissiondateformat": "102" }
25957233 Type 1
Serious
PANTOPRAZOLE SODIUM
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/18/2026
Primary Source Country
EU
Occurrence Country
EU
Reporter Country
EU
Reporter Qualification
Consumer
Literature Reference
--
Company Number
EU-TAKEDA-2025TUS092481
Authority Number
--
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (3)

Gastric ulcer (v28.1) Not Recovered
Hiatus hernia (v28.1) Not Recovered
Gastrooesophageal reflux disease (v28.1) Not Recovered

Drugs (1)

PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) Suspect
Route: 065 | Dosage: 20 MILLIGRAM | Form: -- | Indication: -- | Action: Withdrawn
Auth#: 20987 | Batch#: -- | Structured Dosage: 20.0 (unit: 003) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: No
Recurrences: --

Clinical Narrative

--

Report Duplicates (2)

TAKEDA: EU-TAKEDA-2025TUS092481
MIC: EU-MIC-a0PQP00000qd0Bt2AI

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56686", "safetyreportid": "25957233", "authoritynumb": null, "companynumb": "EU-TAKEDA-2025TUS092481", "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "EU", "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Gastric ulcer", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Hiatus hernia", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Gastrooesophageal reflux disease", "reactionoutcome": 3 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "PANTOPRAZOLE SODIUM", "drugauthorizationnumb": "20987", "drugbatchnumb": null, "drugstructuredosagenumb": 20.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "20 MILLIGRAM", "drugdosageform": null, "drugadministrationroute": "065", "drugindication": null, "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 2, "actiondrug": 1, "activesubstance": { "activesubstancename": "PANTOPRAZOLE SODIUM" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "EU", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "EU", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "TAKEDA", "duplicatenumb": "EU-TAKEDA-2025TUS092481" }, { "duplicatesource": "MIC", "duplicatenumb": "EU-MIC-a0PQP00000qd0Bt2AI" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25957228 Type 1
Serious
DOXYCYCLINE
Report Version
1
Receive Date
10/24/2025
Receipt Date
10/24/2025
Transmission Date
01/18/2026
Primary Source Country
GB
Occurrence Country
GB
Reporter Country
GB
Reporter Qualification
Consumer
Literature Reference
--
Company Number
--
Authority Number
GB-MHRA-MED-202510212235497090-FLJSB
Sender Organization
PFIZER
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
Female
Patient Weight
78.0 kg

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (6)

Anaemia (v28.1) Not Recovered
Palpitations (v28.1) Not Recovered
Decreased appetite (v28.1) Not Recovered
Photosensitivity reaction (v28.1) Not Recovered
Nausea (v28.1) Not Recovered
Headache (v28.1) Not Recovered

Drugs (1)

DOXYCYCLINE (DOXYCYCLINE) Suspect
Route: -- | Dosage: 100 MG, 1X/DAY | Form: -- | Indication: Acne | Action: Withdrawn
Auth#: 50006 | Batch#: -- | Structured Dosage: 100.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 1.0 day | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: No
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20251018

Report Duplicates (1)

MHRA: GB-MHRA-MED-202510212235497090-FLJSB

Raw JSON (click to expand)

{ "_id": "69d4359f3b3830196fa56685", "safetyreportid": "25957228", "authoritynumb": "GB-MHRA-MED-202510212235497090-FLJSB", "companynumb": null, "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "GB", "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": 78.0, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Anaemia", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Palpitations", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Decreased appetite", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Photosensitivity reaction", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Nausea", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Headache", "reactionoutcome": 3 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "DOXYCYCLINE", "drugauthorizationnumb": "50006", "drugbatchnumb": null, "drugstructuredosagenumb": 100.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 1.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "100 MG, 1X/DAY", "drugdosageform": null, "drugadministrationroute": null, "drugindication": "Acne", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 2, "actiondrug": 1, "activesubstance": { "activesubstancename": "DOXYCYCLINE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20251018" }, "primarysource": { "reportercountry": "GB", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "GB", "quarter": "2025Q4", "receiptdate": "2025-10-24T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-24T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "MHRA", "duplicatenumb": "GB-MHRA-MED-202510212235497090-FLJSB" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "PFIZER" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }